Matrix metalloproteinases in the process of invasion and metastasis of breast cancer

Archive of Oncology

Volumn 14, Issue 3-4, 2006, Pages 136-140

  Konjević, Gordana ^a,b   Stanković, Sandra ^a  

^a INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Breast neoplasms; Matrix metalloproteinases; Neoplasm invasiveness; Neoplasm metastasis; Tissue inhibitor of metalloproteinases

Indexed keywords

COLLAGEN TYPE 4; GELATINASE A; GELATINASE B; UROKINASE;

ANGIOGENESIS; BASEMENT MEMBRANE; BREAST CANCER; CANCER INVASION; CANCER STAGING; CELL ADHESION; CELL MOTILITY; CONTACT INHIBITION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME DEGRADATION; EXTRACELLULAR MATRIX; HUMAN; IMMUNOMODULATION; METASTASIS; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; TUMOR GROWTH;

EID: 34147131140     PISSN: 03547310     EISSN: None     Source Type: Journal    
DOI: 10.2298/AOO0604136K     Document Type: Review

References (46)

1. Bracke ME, van Roy FM, Mareel MM. The E-cadherin/catenin complex in invasion and metastasis. Curr Top Microbiol Immunol 1996;213(Pt 1):123.
2. Birchmeier W, Behrens J. Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. Biochem Biophys Acta 1994;1198:11.
3. Maeda M, Shintani Y, Wheelock MJ, Johnson KR. Src activation is not necessary for transforming growth factor (TGF)-beta-mediated epithelial to mesenchymal transitions (EMT) in mammary epithelial cells. PP1 directly inhibits TGF-beta receptors I and II. J Biol Chem 2006;281(1):59-68.
4. Lochter A, Galosy S, Muschler J, Freedman N, Werb Z, Bissel MJ. Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that lead to stable-epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells. J Cell Biol 1997;139:1861-72.
5. Sternlicht MD, Lochter A, Sympson CJ, Huey B, Rougier JP, Gray JW, et al. The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell 1999;98:137-46.
6. Polyak K, Hahn WC. Roots and stems: stem cells in cancer. Nat Med 2006;12(3):296-300.
7. Christiansen JJ, Rajasekaran AK. Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res 2006;66(17):8319-26.
8. Gotzmann J, Mikula M, Eger A, Schulte-Hermann R, Foisner R, Beug H, Mikulits W. Molecular aspects of epithelial cell plasticity: implications for local tumor invasion and metastasis. Mutat Res 2004;566(1):9-20.
9. Knutson KL, Lu H, Stone B, Reiman JM, Behrens MD, Prosperi CM, et al. Immunoediting of cancers may lead to epithelial to mesenchymal transition. J Immunol 2006;177(3):1526-33.
10. Nguyen N, Kuliopulos A, Graham RA, Covic L. Tumor-derived Cyr61 (CCN1) promotes stromal matrix metalloproteinase-1 production and protease-activated receptor 1-dependent migration of breast cancer cells. Cancer Res 2006;66(5):2658-65.
11. Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 2006;172(7):973-81.
12. Jia Y, Zeng ZZ, Markwart SM, Rockwood KF, Ignatoski KM, Ethier SP, et al. Integrin fibronectin receptors in matrix metalloproteinase-1-dependent invasion by breast cancer and mammary epithelial cells. Cancer Res 2004;64(23):8674-81.
13. Hofmann UB, Houben R, Brocker EB, Becker JC. Role of matrix metalloproteinases in melanoma cell invasion. Biochimie 2005;87(3-4):307-14.
14. Mignatti P, Rifkin DB. Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 1993;73:161-95.
15. Laufs S, Schumacher J, Allgayer H. Urokinase-receptor (u-PAR): an essential player in multiple games of cancer: a review on its role in tumor progression, invasion, metastasis, proliferation/ dormancy, clinical outcome and minimal residual disease. Cell Cycle 2006;16:1760-71.
16. Mazzieri R, Masiero L, Zanetta L, Monea S, Onisto M, Garbisa S, et al. Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants. EMBO J 1997;16(9):2319-32.
17. McCawely LJ, Matrisian LM. Matrix metalloproteinases: multifunctional contributors to tumour progression. Mo Med Today 2000;6:149-56.
18. Foda HD, Zucker S. Matrix metalloproteinase in cancer invasion, metastasis and angiogenesis. Drug Discovery Today 2001;6:478-82.
19. Ries C, Petrides PE. Cytokine regulation of matrix metalloproteinase activity and its regulatory dysfunction in disease. Biol Chem Hoppe Seyler 1995;376(6):345-55.
20. Woessner JF Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling, FASEB J 1991;5(8):2145-54.
21. Townson JL, Chambers AF. Dormancy of solitary metastatic cells. CeS Cycle 2006;5(16):1744-50.
22. Indraccolo S, Favaro E, Amadori A. Dormant tumors awaken by a short-term angiogenic burst: the spike hypothesis. Cell Cycle 2006;5(16):1751-5.
23. Seo DW, Li H, Guedez L, Wingfield PT, Diaz T, Salloum R, et al. TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism. Cell 2003;114(2):171-80.
24. Chabottaux V, Sounni NE, Pennington CJ, English WR, van den Brule F, Blacher S, et al. Membrane-type 4 matrix metalloproteinase promotes breast cancer growth and metastases. Cancer Res 2006;66(10):5165-72.
25. Liss M, Sreedhar N, Gilliard G, Keshgegian A, Wallon M. MT1-MMP and TIMP-4 as prognostic markers for survival among patients with small, node-negativeductal carcinomas[abstract]. AACR 2006;3601.
26. Yang JM, O'Neill P, Jin W, Foty R, Medina DJ, Xu Z, et al. Extracellular matrix metalloproteinase inducer (CD147) confers resistance of breast cancer cells to Anoikis through inhibition of Bim. J Biol Chem 2006;281(14):9719-27.
27. Tang Y, Kesavan P, Nakada MT, Yan L. Tumor-stroma interaction: positive feedback regulation of extracellular matrix metalloproteinase inducer (EMMPRIN) expression and matrix metalloproteinase-dependent generation of soluble EMMPRIN. Mol Cancer Res 2004;2(2):73-80.
28. Abraham M, Shapiro S, Lahat N, Miller A. The role of IL-18 and IL-12 in the modulation of matrix metalloproteinases and their tissue inhibitors in monocytic cells. Int Immunol 2002;14(12):1449-57.
29. Mitola S, Strasly M, Prarto M, Ghia P, Bussolino F. IL-12 regulates an endothelial cell-lymphocyte network: effect on metalloproteinase-9 production. J Immunol 2003;171(7):3725-33.
30. Mignatti P, Tsuboi R, Robbins E, Rifkin DB. In vitro angiogenesis on the human amniotic membrane: requirement for basic fibroblast growth factor induced proteinases. J Cell Biol 1989;108:671-82.
31. Stetler-Stevenson WG. Progelatinase A activation during tumor cell invasion. Invest Methods 1995;14:259-68.
32. Jinga DC, Blidaru A, Condrea I, Ardeleanu C, Dragomir C, Szegli G, et al. MMP-9 and MMP-2 gelatinases and TIMP-1 and TIMP-2 inhibitors in breast cancer: correlations with prognostic factors. J Cell Mol Med 2006;10(2):499-510.
33. Matrisian LM. Extracellular proteinases in malignancy. Current Biol 1999;9:R776-8.
34. LaRocca G, Pucci-Minafra I, Marrazzo A, Taormina P, Minafra S. Zymographic detection and clinical correlations of MMP-2 and MMP-9 in breast cancer sera. Br J Cancer 2004;90:1414-21.
35. Ranuncolo SM, Armanasco E, Cresta C, Bal De Kier Joffe E, Puricelli L. Plasma MMP-9 (92 kDa-MMP) activity is useful in the follow-up and in the assessment of prognosis in breast cancer patients. Int J Cancer 2003;106(5):745-51.
36. th Meeting of the European Association for Cancer Research; 2006; Budapest, Hungary; 2006. p. 194.
37. Thompson EW, Reich R, Shirna TB, Albini A, Graf J, Martin GR, et al Differential regulation of growth and invasiveness of MCF-7 breast cancer cells by antiestrogens. Cancer Res 1988;48:6764-8.
38. Van den Brule FA, Engel J, Stetler-Stevenson WG, Liu FT, Sobel ME, Castronovo V. Genes involved in tumor invasion and metastasis are differentially modulated by estradiol and progestin in human breast-cancer cells. Int J Cancer 1992;52:653-7.
39. Yu D, Wang SS, Dulski KM, Tsai CM, Nicolson GL, Hung MC. c-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties. Cancer Res 1994;54:3260-6.
40. Pellikainen JM, Ropponen KM, Kataja VV, Kellokoski JK, Eskelinen MJ, Kosma VM Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clin Cancer Res 2004;10(22):7621-8.
41. Liu XW, Taube ME, Jung KK, Dong Z, Lee YJ, Roshy S, Sloane BF, et al. Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells from extrinsic cell death: a potential oncogenic activity of tissue inhibitor of metalloproteinase-1. Cancer Res 2005;65(3):898-906.
42. Pellikainen JM, Ropponen KM, Kataja VV, Kellokoski JK, Eskelinen MJ, Kosma VM. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clin Cancer Res 2004;10(22):7621-8.
43. Brenton JD, Carey LA, Ahmed AA, Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol 2005;23(29):7350-60.
44. Chang HY, Nuyten DS, Sneddon JB, Hastie T, Tibshirani R, Sorlie T, et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Nad Acad Sci U S A 2005;102:3738-43.
45. Bissell MJ, Radisky D. Putting tumors in context. Nat Rev Cancer 2001;1:46-54.
46. Chang HY Sneddon JB, Alizadeh AA, Sood R, West RB, Montgomery K, et al. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol 2004;2(2):E7.